We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Board of Directors of Patheon Inc. today announced that Robert C. Tedford, the Company's Chief Executive Officer, has advised the Board that he has decided to retire at this time in order to pursue a number of personal interests.
BioSante Pharmaceuticals, Inc. today announced that it will present positive results of several pre-clinical studies, demonstrating that its calcium phosphate (CaP) nanoparticle-based vaccine adjuvant, BioVant, may serve as an adjuvant for the development of an effective flu virus vaccine, including the potentially pandemic H5N1 bird flu.
The Botswana-Harvard Partnership has discontinued vaccinations in the Phase I HIV Vaccine Trial known as HVTN 059, announced Joseph Makhema, the program's director.
U.S.-based Adeza has submitted a new drug application (NDA) to the U.S. FDA for Gestiva, the company's drug candidate to prevent preterm birth in women with a history of preterm delivery.
Janssen-Cilag International has submitted a marketing authorization application to the European Medicines Evaluation Agency for a new, once-a-day drug to treat schizophrenia.
Aceto Corporation, a global distributor of chemically-derived pharmaceuticals, biopharmaceuticals, specialty chemicals and agrochemicals, today announced results of operations for its fiscal 2006 third quarter and nine months ended March 31, 2006.
Pharmaceutical group Sanofi-Aventis has reported that first-quarter net profit had surged by 53.6 percent with a big injection from the sale of the patent for diabetes treatment Exubera to US group Pfizer.